Do analysts rate JATT or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,565.09%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings & valuation, JATT or MDCX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is JATT or MDCX more profitable?

JATT Acquisition's return on equity of -49.58% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Medicus Pharma N/A -3,137.84% -311.33%

Does the media prefer JATT or MDCX?

In the previous week, Medicus Pharma had 7 more articles in the media than JATT Acquisition. MarketBeat recorded 8 mentions for Medicus Pharma and 1 mentions for JATT Acquisition. Medicus Pharma's average media sentiment score of 0.30 beat JATT Acquisition's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment JATT Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, MDCX or LONA?

Athira Pharma is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Athira Pharma N/A N/A -$105.61M -$5.21 N/A

Is MDCX or LONA more profitable?

Athira Pharma's return on equity of -381.01% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Athira Pharma N/A -381.01% -225.74%

Is GANX or MDCX more profitable?

Gain Therapeutics' return on equity of -201.44% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Medicus Pharma N/A -3,137.84% -311.33%

Does the media refer more to GANX or MDCX?

In the previous week, Medicus Pharma had 5 more articles in the media than Gain Therapeutics. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.64 beat Medicus Pharma's score of 0.30 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate EXOZ or MDCX?

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,565.09%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is EXOZ or MDCX more profitable?

eXoZymes' return on equity of -220.63% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Medicus Pharma N/A -3,137.84% -311.33%

Does the media refer more to EXOZ or MDCX?

In the previous week, Medicus Pharma had 6 more articles in the media than eXoZymes. MarketBeat recorded 8 mentions for Medicus Pharma and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Medicus Pharma's score of 0.30 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CLNN or MDCX more profitable?

Medicus Pharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% Medicus Pharma N/A -3,137.84% -311.33%

Medicus Pharma (MDCX) Competitors

$0.34 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.32 -0.01 (-3.76%)

As of 09:23 AM Eastern

Compare

MDCX vs. JATT, LONA, GANX, EXOZ, and CLNN

Should you buy Medicus Pharma stock or one of its competitors? MarketBeat compares Medicus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medicus Pharma include JATT Acquisition (JATT), Athira Pharma (LONA), Gain Therapeutics (GANX), eXoZymes (EXOZ), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry.

How does Medicus Pharma compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

JATT Acquisition's return on equity of -49.58% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Medicus Pharma	N/A	-3,137.84%	-311.33%

48.0% of JATT Acquisition shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,565.09%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medicus Pharma had 7 more articles in the media than JATT Acquisition. MarketBeat recorded 8 mentions for Medicus Pharma and 1 mentions for JATT Acquisition. Medicus Pharma's average media sentiment score of 0.30 beat JATT Acquisition's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

JATT Acquisition and Medicus Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicus Pharma compare to Athira Pharma?

Medicus Pharma (NASDAQ:MDCX) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Athira Pharma's return on equity of -381.01% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Athira Pharma	N/A	-381.01%	-225.74%

Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 2,565.09%. Athira Pharma has a consensus target price of $15.00, suggesting a potential upside of 79.64%. Given Medicus Pharma's higher possible upside, equities research analysts clearly believe Medicus Pharma is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

57.1% of Athira Pharma shares are held by institutional investors. 8.1% of Medicus Pharma shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Medicus Pharma has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

Athira Pharma is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

In the previous week, Medicus Pharma had 7 more articles in the media than Athira Pharma. MarketBeat recorded 8 mentions for Medicus Pharma and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Medicus Pharma's score of 0.30 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Medicus Pharma	Neutral
Athira Pharma	Very Positive

Summary

Athira Pharma beats Medicus Pharma on 8 of the 13 factors compared between the two stocks.

How does Medicus Pharma compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Gain Therapeutics' return on equity of -201.44% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Gain Therapeutics has higher revenue and earnings than Medicus Pharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,433.04	-$20.16M	-$0.58	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Gain Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

12.0% of Gain Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Medicus Pharma had 5 more articles in the media than Gain Therapeutics. MarketBeat recorded 8 mentions for Medicus Pharma and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.64 beat Medicus Pharma's score of 0.30 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Gain Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 405.95%. Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,565.09%. Given Medicus Pharma's higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Gain Therapeutics beats Medicus Pharma on 10 of the 14 factors compared between the two stocks.

How does Medicus Pharma compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Medicus Pharma had 6 more articles in the media than eXoZymes. MarketBeat recorded 8 mentions for Medicus Pharma and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Medicus Pharma's score of 0.30 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

eXoZymes has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

eXoZymes' return on equity of -220.63% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Medicus Pharma	N/A	-3,137.84%	-311.33%

eXoZymes has higher revenue and earnings than Medicus Pharma. eXoZymes is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	860.11	-$9.16M	-$1.14	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,565.09%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

eXoZymes beats Medicus Pharma on 7 of the 12 factors compared between the two stocks.

How does Medicus Pharma compare to Clene?

Clene (NASDAQ:CLNN) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Medicus Pharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Clene currently has a consensus target price of $33.25, indicating a potential upside of 469.35%. Medicus Pharma has a consensus target price of $9.00, indicating a potential upside of 2,565.09%. Given Medicus Pharma's higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

23.3% of Clene shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Medicus Pharma had 7 more articles in the media than Clene. MarketBeat recorded 8 mentions for Medicus Pharma and 1 mentions for Clene. Clene's average media sentiment score of 1.89 beat Medicus Pharma's score of 0.30 indicating that Clene is being referred to more favorably in the media.

Company	Overall Sentiment
Clene	Very Positive
Medicus Pharma	Neutral

Clene has higher revenue and earnings than Medicus Pharma. Clene is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	373.18	-$26.17M	-$3.20	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Clene has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

Summary

Clene beats Medicus Pharma on 10 of the 15 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDCX vs. The Competition

Export

Metric	Medicus Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.13M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.13	20.00	24.00	24.42
Price / Sales	N/A	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	N/A	8.32	10.55	6.82
Net Income	-$35.46M	$23.94M	$3.57B	$337.56M
7 Day Performance	0.45%	1.84%	0.59%	1.16%
1 Month Performance	12.19%	-0.04%	1.55%	3.16%
1 Year Performance	-87.01%	44.82%	25.41%	30.60%

Medicus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDCX Medicus Pharma	2.4552 of 5 stars	$0.34 flat	$9.00 +2,565.1%	-87.0%	$19.13M	N/A	N/A	N/A
JATT JATT Acquisition	N/A	$10.47 +0.4%	N/A	+760.0%	$81.66M	N/A	N/A	3
LONA Athira Pharma	3.9144 of 5 stars	$8.61 -0.2%	$15.00 +74.2%	N/A	$80.85M	N/A	N/A	40	Positive News
GANX Gain Therapeutics	2.1744 of 5 stars	$1.86 +3.9%	$8.50 +357.0%	-2.9%	$79.33M	$50K	N/A	20
EXOZ eXoZymes	0.6135 of 5 stars	$9.35 -1.2%	N/A	-44.6%	$79.29M	$70K	N/A	29	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDCX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicus Pharma (MDCX) Competitors

MDCX vs. JATT, LONA, GANX, EXOZ, and CLNN

How does Medicus Pharma compare to JATT Acquisition?

Summary

How does Medicus Pharma compare to Athira Pharma?

Summary

How does Medicus Pharma compare to Gain Therapeutics?

Summary

How does Medicus Pharma compare to eXoZymes?

Summary

How does Medicus Pharma compare to Clene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicus Pharma (MDCX) Competitors

MDCX vs. JATT, LONA, GANX, EXOZ, and CLNN

How does Medicus Pharma compare to JATT Acquisition?

Is JATT or MDCX more profitable?

Do institutionals and insiders hold more shares of JATT or MDCX?

Which has higher earnings & valuation, JATT or MDCX?

Do analysts rate JATT or MDCX?

Does the media prefer JATT or MDCX?

Summary

How does Medicus Pharma compare to Athira Pharma?

Is MDCX or LONA more profitable?

Do analysts rate MDCX or LONA?

Do institutionals & insiders hold more shares of MDCX or LONA?

Which has more risk and volatility, MDCX or LONA?

Which has better earnings & valuation, MDCX or LONA?

Does the media prefer MDCX or LONA?

Summary

How does Medicus Pharma compare to Gain Therapeutics?

Is GANX or MDCX more profitable?

Which has stronger earnings and valuation, GANX or MDCX?

Which has more volatility and risk, GANX or MDCX?

Do insiders & institutionals believe in GANX or MDCX?

Does the media refer more to GANX or MDCX?

Do analysts rate GANX or MDCX?

Summary

How does Medicus Pharma compare to eXoZymes?

Does the media refer more to EXOZ or MDCX?

Which has more risk and volatility, EXOZ or MDCX?

Is EXOZ or MDCX more profitable?

Which has better valuation and earnings, EXOZ or MDCX?

Do analysts rate EXOZ or MDCX?

Summary

How does Medicus Pharma compare to Clene?

Is CLNN or MDCX more profitable?

Do analysts rate CLNN or MDCX?

Do institutionals and insiders believe in CLNN or MDCX?

Does the media favor CLNN or MDCX?

Which has better earnings and valuation, CLNN or MDCX?

Which has more volatility and risk, CLNN or MDCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX vs. The Competition

Medicus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools